KalVista Pharmaceuticals, Inc. (FRA:4XC1)

Market Cap	859.43M +53.3%
Revenue (ttm)	62.70M
Net Income	-139.92M
EPS	-2.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	108
Open	16.30
Previous Close	14.20
Day's Range	16.30 - 16.60
52-Week Range	9.00 - 16.60
Beta	n/a
RSI	68.11
Earnings Date	Mar 25, 2026

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmace...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Benjamin Palleiko
• Employees: 275
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4XC1

Financial Performance

Financial numbers in USD